PAR-23-157 - Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
is used for the submission of applications to the following Notices of Special Interest (NOSIs)
Active NOSIs
Title |
Notice Number |
Organization |
Release Date |
Expiration Date |
Activity Code(s) |
Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research |
NOT-CA-22-037 |
NCI , NHLBI , NIA , NIDA , NIMH , NINR , OBSSR
|
Jan 27, 2022 |
Mar 9, 2024
|
R01, R03, R21, R43/R44, R41/R42, R33, R34, R61/R33 |
Notice of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Population, Clinical and Applied Prevention Mechanisms of Health Effects |
NOT-OD-22-023 |
ODP , NCI , NIDA , NIMHD , NIDCR
|
Dec 8, 2021 |
May 9, 2024
|
R21, R01, 333, R34, R03, R61/R33 |
Expired NOSIs
Title |
Notice Number |
Organization |
Release Date |
Expiration Date |
Activity Code(s) |
Notice of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Basic Mechanisms of Health Effects |
NOT-OD-22-022 |
ODP NIDCR NCI NIEHS NIDA
|
Dec 9, 2021 |
May 9, 2023
|
R01, R61/R33, R21, 333, R03 |
Notice of Special Interest (NOSI):Sleep and Substance Use Disorders |
NOT-DA-20-021 |
NIDA
|
Mar 25, 2020 |
Sep 8, 2023
|
R01, R03, R21, K99/R00, R61/R33 |
|